Publication: The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
dc.contributor.coauthor | Akyildiz, Arif | |
dc.contributor.coauthor | Guven, Deniz Can | |
dc.contributor.coauthor | Ozluk, Ahmet Anil | |
dc.contributor.coauthor | Ismayilov, Rashad | |
dc.contributor.coauthor | Mutlu, Emel | |
dc.contributor.coauthor | Unal, Olcun Umit | |
dc.contributor.coauthor | Yildiz, Ibrahim | |
dc.contributor.coauthor | Iriagac, Yakup | |
dc.contributor.coauthor | Turhal, Serdar | |
dc.contributor.coauthor | Bayram, Ertugrul | |
dc.contributor.coauthor | Telli, Tugba Akin | |
dc.contributor.coauthor | Turkoz, Fatma Paksoy | |
dc.contributor.coauthor | Ozcelik, Melike | |
dc.contributor.coauthor | Erciyestepe, Mert | |
dc.contributor.coauthor | Selvi, Oguzhan | |
dc.contributor.coauthor | Gulbagci, Burcu | |
dc.contributor.coauthor | Erturk, Ismail | |
dc.contributor.coauthor | Isleyen, Zehra Sucuoglu | |
dc.contributor.coauthor | Kahraman, Seda | |
dc.contributor.coauthor | Akdag, Mutianur Ozkorkmaz | |
dc.contributor.coauthor | Hamitoglu, Buket | |
dc.contributor.coauthor | Unek, Ilkay Tugba | |
dc.contributor.coauthor | Unal, Caglar | |
dc.contributor.coauthor | Hacibekiroglu, İlhan | |
dc.contributor.coauthor | Arslan, Cagatay | |
dc.contributor.coauthor | Azizy, Abdulmunir | |
dc.contributor.coauthor | Helvaci, Kaan | |
dc.contributor.coauthor | Demirci, Umut | |
dc.contributor.coauthor | Dizdar, Omer | |
dc.contributor.coauthor | Basaran, Mert | |
dc.contributor.coauthor | Goker, Erdem | |
dc.contributor.coauthor | Sendur, Mehmet Ali | |
dc.contributor.coauthor | Yalcin, Suayib | |
dc.contributor.department | KUH (Koç University Hospital) | |
dc.contributor.kuauthor | Akbaş, Sinem | |
dc.contributor.schoolcollegeinstitute | KUH (KOÇ UNIVERSITY HOSPITAL) | |
dc.date.accessioned | 2025-01-19T10:27:47Z | |
dc.date.issued | 2023 | |
dc.description.abstract | The aim of the study was to evaluate the real-world clinical outcomes of atezolizumab and bevacizumab (Atez/Bev) as the initial therapy for advanced hepatocellular carcinoma (HCC). We retrospectively analyzed 65 patients treated with Atez/Bev for advanced HCC from 22 institutions in Turkey between September 2020 and March 2023. Responses were evaluated by RECIST v1.1 criteria. The median progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Cox regression model was employed to conduct multivariate analyses. The median age was 65 (range, 22-89) years, and 83.1% of the patients were male. A total of 1.5% achieved a complete response, 35.4% had a partial response, 36.9% had stable disease, and 26.2% had progressive disease. The disease control rate was 73.8% and associated with alpha-fetoprotein levels at diagnosis and concomitant antibiotic use. The incidence rates of any grade and grade ≥ 3 adverse events were 29.2% and 10.7%, respectively. At a median follow-up of 11.3 (3.4-33.3) months, the median PFS and OS were 5.1 (95% CI: 3-7.3) and 18.1 (95% CI: 6.2-29.9) months, respectively. In univariate analyses, ECOG-PS ≥ 1 (relative to 0), Child-Pugh class B (relative to A), neutrophil-to-lymphocyte ratio (NLR) > 2.9 (relative to ≤ 2.9), and concomitant antibiotic use significantly increased the overall risk of mortality. Multivariate analysis revealed that ECOG-PS ≥ 1 (HR: 2.69, P =.02), NLR > 2.9 (HR: 2.94, P =.017), and concomitant antibiotic use (HR: 4.18, P =.003) were independent predictors of OS. Atez/Bev is an effective and safe first-line therapy for advanced-stage HCC in a real-world setting. The survival benefit was especially promising in patients with a ECOG-PS score of 0, Child-Pugh class A, lower NLR, and patients who were not exposed to antibiotics during the treatment. | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 45 | |
dc.description.openaccess | All Open Access; Gold Open Access; Green Open Access | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.volume | 102 | |
dc.identifier.doi | 10.1097/MD.0000000000035950 | |
dc.identifier.eissn | 1473-5628 | |
dc.identifier.issn | 0025-7974 | |
dc.identifier.quartile | Q2 | |
dc.identifier.scopus | 2-s2.0-85176889390 | |
dc.identifier.uri | https://doi.org/10.1097/MD.0000000000035950 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/25606 | |
dc.identifier.wos | 1103423000055 | |
dc.keywords | Atezolizumab | |
dc.keywords | Bevacizumab | |
dc.keywords | Hepatocellular carcinoma | |
dc.keywords | Immunotherapy | |
dc.language.iso | eng | |
dc.publisher | Lippincott Williams and Wilkins | |
dc.relation.ispartof | Medicine (United States) | |
dc.subject | Radiology, nuclear medicine and medical imaging | |
dc.title | The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Akbaş, Sinem | |
local.publication.orgunit1 | KUH (KOÇ UNIVERSITY HOSPITAL) | |
local.publication.orgunit2 | KUH (Koç University Hospital) | |
relation.isOrgUnitOfPublication | f91d21f0-6b13-46ce-939a-db68e4c8d2ab | |
relation.isOrgUnitOfPublication.latestForDiscovery | f91d21f0-6b13-46ce-939a-db68e4c8d2ab | |
relation.isParentOrgUnitOfPublication | 055775c9-9efe-43ec-814f-f6d771fa6dee | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 055775c9-9efe-43ec-814f-f6d771fa6dee |
Files
Original bundle
1 - 1 of 1